Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.75 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | GC | P02774 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | RXRA | P19793 | 1/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.75 |
| ▸ | CNR1 | P21554 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005439 | 1.00 | VDR (0.75) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14030105 | 1.00 | VDR (0.75) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL3222600 | 1.00 | VDR (0.75) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL27758384 | 1.00 | VDR (0.75) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14005326 | 0.95 | VDR (0.74) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL3219460 | 0.94 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14489389 | 0.94 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14005553 | 0.94 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14005545 | 0.94 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL16357615 | 0.94 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080280860-A1 | Use of Vitamin D Compounds to Treat Endometriosis | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080280860-A1 | Use of Vitamin D Compounds to Treat Endometriosis | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| WO-2008043857-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL SPA (IT) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20070054887-A1 | Methods for treating bladder dysfunction | BIOXELL S.P.A (IT) | 2007-03-08 | — | — | US | disclosed |
| US-20070054887-A1 | Methods for treating bladder dysfunction | BIOXELL S.P.A (IT) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | VDR 5/4885MAPT 4547/4885ADORA3 2411/4885 |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | VDR, GC, CYP24A1 | VDR 1/4885MAPT 2629/4885ADORA3 57/4885 |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | VDR, CYP24A1, CYP27B1 | VDR 1/4885MAPT 4682/4885ADORA3 1375/4885 |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 3603/4885ADORA3 342/4885 |
| US-20080280860-A1 | Use of Vitamin D Compounds to Treat Endometriosis | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 4393/4885ADORA3 619/4885 |
| US-20070054887-A1 | Methods for treating bladder dysfunction | CYP27B1, CYP24A1, VDR | VDR 3/4885MAPT 3931/4885ADORA3 842/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | VDR 2/4885MAPT 4570/4885ADORA3 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.